NASDAQ:MORF Morphic (MORF) Stock Forecast, Price & News $36.68 -14.72 (-28.64%) (As of 09/22/2023 ET) Add Compare Share Share Today's Range$31.55▼$52.7150-Day Range$50.75▼$59.3452-Week Range$23.03▼$63.08Volume5.87 million shsAverage Volume489,599 shsMarket Capitalization$1.76 billionP/E RatioN/ADividend YieldN/APrice Target$73.43 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability Morphic MarketRank™ ForecastAnalyst RatingModerate Buy2.80 Rating ScoreUpside/Downside100.2% Upside$73.43 Price TargetShort InterestBearish5.93% of Shares Sold ShortDividend StrengthN/ASustainability-0.57Upright™ Environmental ScoreNews SentimentN/AInsider TradingSelling Shares$1.50 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($3.80) to ($4.45) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.07 out of 5 starsMedical Sector585th out of 968 stocksPharmaceutical Preparations Industry266th out of 445 stocks 3.4 Analyst's Opinion Consensus RatingMorphic has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $73.43, Morphic has a forecasted upside of 100.2% from its current price of $36.68.Amount of Analyst CoverageMorphic has only been the subject of 2 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted5.93% of the outstanding shares of Morphic have been sold short.Short Interest Ratio / Days to CoverMorphic has a short interest ratio ("days to cover") of 7.Change versus previous monthShort interest in Morphic has recently increased by 8.40%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldMorphic does not currently pay a dividend.Dividend GrowthMorphic does not have a long track record of dividend growth. Previous Next 4.8 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreMorphic has received a 76.58% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Preclinical research services for physical health" and "Clinical research services for physiological diseases " products. See details.Environmental SustainabilityThe Environmental Impact score for Morphic is -0.57. Previous Next 0.6 News and Social Media Coverage Search InterestOnly 1 people have searched for MORF on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat Follows2 people have added Morphic to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Morphic insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,497,146.00 in company stock.Percentage Held by Insiders28.10% of the stock of Morphic is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions80.66% of the stock of Morphic is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Morphic are expected to decrease in the coming year, from ($3.80) to ($4.45) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Morphic is -11.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Morphic is -11.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMorphic has a P/B Ratio of 4.05. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Morphic (NASDAQ:MORF) StockMorphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, and metabolic diseases, as well as fibrosis and cancer. Its lead product candidate MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation is in Phase 2 clinical trials for the treatment of inflammatory bowel disease. The company's products in pipeline include Next Gen a4ß7 Inhibitors for additional potential GI indications, such as EGIDs, pouchitis, etc.; avß8 for the treatment of Myelofibrosis and solid tumor; and fibronectin integrin for pulmonary hypertensive. In addition, it has a license agreement with Janssen to discover and develop novel integrin therapeutics; collaboration agreement with Schrödinger for integrin targets; and license agreement with Children's Medical Center Corporation to develop and commercialize products worldwide for any therapeutic or diagnostic use in humans and veterinary applications. The company was incorporated in 2014 and is headquartered in Waltham, Massachusetts.Read More MORF Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MORF Stock News HeadlinesSeptember 9, 2023 | finance.yahoo.comMorphic Holding Inc CFO and COO Marc Schegerin Sells 20,000 SharesAugust 29, 2023 | finance.yahoo.comMorphic Announces Participation in 2023 Wells Fargo Healthcare ConferenceSeptember 22, 2023 | Legacy Research (Ad)The Real Reason They Murdered JFK?Some people believe JFK was murdered because of his executive order 11110 that would have reduced the power of the Federal Reserve. Regardless if that’s true or not… The Fed is now involved in a new controversy that could have drastic consequences for the US dollar.August 9, 2023 | seekingalpha.comStifel cuts Morphic to hold, doesn't see it as near-term M&A targetAugust 9, 2023 | finance.yahoo.comMorphic to Present at the Canaccord Genuity 43rd Annual Growth ConferenceAugust 7, 2023 | finance.yahoo.comMorphic Holding, Inc.'s (NASDAQ:MORF) large institutional owners must be happy as stock continues to impress, up 4.4% over the past weekAugust 6, 2023 | fool.comMorphic (NASDAQ: MORF)August 3, 2023 | finance.yahoo.comMorphic Announces Corporate Highlights and Financial Results for the Second Quarter 2023September 22, 2023 | Legacy Research (Ad)The Real Reason They Murdered JFK?Some people believe JFK was murdered because of his executive order 11110 that would have reduced the power of the Federal Reserve. Regardless if that’s true or not… The Fed is now involved in a new controversy that could have drastic consequences for the US dollar.August 3, 2023 | finance.yahoo.comMorphic Holding, Inc. (MORF) Reports Q2 Loss, Lags Revenue EstimatesJuly 26, 2023 | msn.comAlkermes (ALKS) Tops Q2 Earnings and Revenue EstimatesJuly 20, 2023 | markets.businessinsider.comMorphic Holding (MORF) Receives a New Rating from Berenberg BankJuly 10, 2023 | seekingalpha.comMorphic: High Valuation Not Justified By Data, Development Status, Or CashJune 6, 2023 | finance.yahoo.comMorphic to Present at the Jefferies Global Healthcare ConferenceJune 6, 2023 | benzinga.comDirector at Morphic Holding Acquires Company Stock Options Worth 12,535 SharesMay 26, 2023 | finance.yahoo.comHere's Why We're Not At All Concerned With Morphic Holding's (NASDAQ:MORF) Cash Burn SituationMay 12, 2023 | finance.yahoo.comMorphic to Present at 2023 RBC Capital Markets Global Healthcare ConferenceMay 11, 2023 | finance.yahoo.comMorphic Presents New Biomarker Data at DDW 2023 Supporting MORF-057 Program in Ulcerative ColitisMay 10, 2023 | benzinga.comPresident at Morphic Holding Exercises Options Worth $934KMay 6, 2023 | finance.yahoo.comMorphic Holding Founder Acquires 16% More Stock \May 3, 2023 | finance.yahoo.comMorphic Therapeutic Announces Pricing of $240.0 Million Public OfferingApril 30, 2023 | finance.yahoo.comWhat Does The Future Hold For Morphic Holding, Inc. (NASDAQ:MORF)? These Analysts Have Been Cutting Their EstimatesApril 25, 2023 | seekingalpha.comMorphic: Positive Phase 2a UC Trial, Top M&A Candidate In 2023April 25, 2023 | finance.yahoo.comMorphic Holding, Inc. (MORF) Reports Q1 Loss, Lags Revenue EstimatesApril 25, 2023 | finance.yahoo.comMorphic Therapeutic's Ulcerative Colitis Candidate Shows Clinically Meaningful Improvements Across Measures, Stock SoarsApril 25, 2023 | finance.yahoo.comMorphic Announces Corporate Highlights and Financial Results for the First Quarter 2023April 25, 2023 | finance.yahoo.comMorphic Reports Positive Topline Results of the EMERALD-1 UC Main Cohort; Orally Administered MORF-057 Achieves Primary Endpoint and Demonstrates Clinically Meaningful Improvements Across Secondary and Exploratory MeasuresSee More Headlines Receive MORF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Morphic and its competitors with MarketBeat's FREE daily newsletter. Email Address MORF Company Calendar Last Earnings8/03/2023Today9/22/2023Next Earnings (Estimated)11/01/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MORF CUSIPN/A CIK1679363 Webwww.morphictx.com Phone(781) 996-0955FaxN/AEmployees110Year FoundedN/APrice Target and Rating Average Stock Price Forecast$73.43 High Stock Price Forecast$106.00 Low Stock Price Forecast$56.00 Forecasted Upside/Downside+90.7%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($3.24) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-59,040,000.00 Net Margins-92.38% Pretax Margin-1,484.46% Return on Equity-27.71% Return on Assets-26.59% Debt Debt-to-Equity RatioN/A Current Ratio41.70 Quick Ratio41.70 Sales & Book Value Annual Sales$70.81 million Price / Sales26.05 Cash FlowN/A Price / Cash FlowN/A Book Value$9.06 per share Price / Book4.25Miscellaneous Outstanding Shares47,920,000Free Float34,457,000Market Cap$1.84 billion OptionableNot Optionable Beta1.10 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesDr. Praveen P. Tipirneni M.D. (Age 55)CEO, MD & Director Comp: $991.33kDr. Bruce N. Rogers Ph.D. (Age 54)Pres Comp: $787.88kDr. Timothy A. Springer Ph.D. (Age 75)Founder, Independent Director & Member of Scientific Advisory Board Comp: $40kDr. Marc Schegerin M.B.A. (Age 47)M.D., CFO & COO Comp: $722.38kMr. Robert E. Farrell Jr. (Age 58)CPA, CPA, Sr. VP of Fin. & Chief Accounting Officer Dr. Blaise Lippa Ph.D.Chief Scientific OfficerMr. William D. DeVaul Esq. (Age 52)Gen. Counsel & Sec. Mr. Aaron PeltaSr. VP of Bus. & Corp. Devel.Ms. Joanne GibbonsSr. VP of Regulatory AffairsMore ExecutivesKey CompetitorsNuvalentNASDAQ:NUVLZai LabNASDAQ:ZLABMaravai LifeSciencesNASDAQ:MRVIUltragenyx PharmaceuticalNASDAQ:RAREXenon PharmaceuticalsNASDAQ:XENEView All CompetitorsInsiders & InstitutionsMarc SchegerinSold 20,000 sharesTotal: $1.09 M ($54.34/share)Wolverine Trading LLCBought 3,962 shares on 8/23/2023Ownership: 0.008%Affinity Asset Advisors LLCBought 66,024 shares on 8/21/2023Ownership: 0.421%California State Teachers Retirement SystemBought 5,701 shares on 8/21/2023Ownership: 0.071%Teachers Retirement System of The State of KentuckySold 5,569 shares on 8/21/2023Ownership: 0.031%View All Insider TransactionsView All Institutional Transactions MORF Stock - Frequently Asked Questions Should I buy or sell Morphic stock right now? 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Morphic in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" MORF shares. View MORF analyst ratings or view top-rated stocks. What is Morphic's stock price forecast for 2023? 5 brokerages have issued twelve-month target prices for Morphic's shares. Their MORF share price forecasts range from $56.00 to $106.00. On average, they predict the company's stock price to reach $73.43 in the next year. This suggests a possible upside of 90.7% from the stock's current price. View analysts price targets for MORF or view top-rated stocks among Wall Street analysts. How have MORF shares performed in 2023? Morphic's stock was trading at $26.75 at the start of the year. Since then, MORF shares have increased by 43.9% and is now trading at $38.50. View the best growth stocks for 2023 here. When is Morphic's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023. View our MORF earnings forecast. How were Morphic's earnings last quarter? Morphic Holding, Inc. (NASDAQ:MORF) posted its quarterly earnings results on Thursday, August, 3rd. The company reported ($0.92) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.90) by $0.02. Morphic had a negative trailing twelve-month return on equity of 27.71% and a negative net margin of 92.38%. What ETFs hold Morphic's stock? ETFs with the largest weight of Morphic (NASDAQ:MORF) stock in their portfolio include Alpha Architect U.S. Quantitative Momentum ETF (QMOM), ALPS Medical Breakthroughs ETF (SBIO), Invesco Dorsey Wright Healthcare Momentum ETF (PTH), SPDR S&P Biotech ETF (XBI), Virtus LifeSci Biotech Clinical Trials ETF (BBC) and Direxion Daily S&P Biotech Bull 3x Shares (LABU).First Trust Small Cap Growth AlphaDEX Fund (FYC). What other stocks do shareholders of Morphic own? Based on aggregate information from My MarketBeat watchlists, some companies that other Morphic investors own include Fulcrum Therapeutics (FULC), Akero Therapeutics (AKRO), AVEO Pharmaceuticals (AVEO), Atreca (BCEL), CymaBay Therapeutics (CBAY), Chiasma (CHMA), Clovis Oncology (CLVS), Gritstone bio (GRTS), Idera Pharmaceuticals (IDRA) and Kaleido Biosciences (KLDO). When did Morphic IPO? (MORF) raised $75 million in an initial public offering (IPO) on Thursday, June 27th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. Jefferies, Cowen, BMO Capital Markets and Wells Fargo Securities acted as the underwriters for the IPO. What is Morphic's stock symbol? Morphic trades on the NASDAQ under the ticker symbol "MORF." Who are Morphic's major shareholders? Morphic's stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (5.74%), State Street Corp (3.62%), Alliancebernstein L.P. (2.42%), Holocene Advisors LP (1.77%), Geode Capital Management LLC (1.38%) and Driehaus Capital Management LLC (1.19%). Insiders that own company stock include Alexey Lugovskoy, Amir Nashat, Bruce Rogers, Fund V Gp LP Omega, Fund V LP Omega, Marc Schegerin, Peter Linde, Praveen P Tipirneni, Robert E Farrell Jr, Robert E Farrell, Jr, Timothy A Springer, Timothy A Springer and William Devaul. View institutional ownership trends. How do I buy shares of Morphic? Shares of MORF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Morphic's stock price today? One share of MORF stock can currently be purchased for approximately $38.50. How much money does Morphic make? Morphic (NASDAQ:MORF) has a market capitalization of $1.84 billion and generates $70.81 million in revenue each year. The company earns $-59,040,000.00 in net income (profit) each year or ($3.24) on an earnings per share basis. How many employees does Morphic have? The company employs 110 workers across the globe. How can I contact Morphic? Morphic's mailing address is 35 Gatehouse Drive A2, Waltham MA, 02451. The official website for the company is www.morphictx.com. The company can be reached via phone at (781) 996-0955. This page (NASDAQ:MORF) was last updated on 9/22/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Morphic Holding, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.